You are leaving Lundbeck.com/US

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit.

Click here to proceed

Cancel

Newsroom

Lundbeck US Newsroom

Here you will find the latest news, stories and insights from Lundbeck US. Lundbeck is a global biopharmaceutical company solely focused on the brain, and our ~1,000 U.S. employees are committed to advancing brain health and transforming lives.  

Filter within articles

Type Title Published
News Release JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults Dec 18, 2024
Feature Lundbeck US Charitable Fund Publishes 2023 Impact Report Dec 11, 2024
News Release Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline Oct 14, 2024
News Release Thomas Gibbs recognized as 2024 PharmaVoice 100 standout leader Oct 8, 2024
News Release Barbara Corcoran announces collaboration with Otsuka and Lundbeck to raise awareness of agitation in Alzheimer’s dementia Sep 26, 2024
News Release Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2024 Jul 31, 2024
News Release Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) Jun 25, 2024
News Release Lundbeck to Present a Breadth of Migraine and Cluster Headache Data at the 66th Annual Scientific Meeting of the American Headache Society Jun 13, 2024
News Release Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults May 28, 2024
News Release Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology Apr 9, 2024

The information in the press releases on these pages are factually acurate on the date of publication. These press releases remain on Lundbeck's website for historical purposes only. Lundbeck assumes no duty to update the information to reflect subsequent developments. Readers should not rely on the information on these pages as current or accurate after their publication dates.

For general media inquiries, contact:

Molly Poarch
Vice President, US Corporate Affairs
Email: MOPC@lundbeck.com
Phone: 224-602-7831